奥希替尼治疗EGFR T790M阳性晚期NSCLC软脑膜转移:AURA分析
本文回顾性分析AURA项目(AURA扩展、AURA2、AURA17、AURA3)中22例EGFR T790M阳性晚期NSCLC软脑膜转移患者,接受奥希替尼80 mg每日一次治疗。软脑膜转移客观缓解率为55%(95%CI 32-76),中位软脑膜无进展生存期11.1个月,中位总生存期18.8个月。纵向分析显示AURA LM与BLOOM研究中非中枢神经系统与软脑膜反应相似。
要点
- 奥希替尼80 mg qd在EGFR T790M阳性NSCLC软脑膜转移中客观缓解率达55%。
- 中位软脑膜无进展生存期11.1个月,中位总生存期18.8个月。
- 纵向分析显示AURA LM与BLOOM研究的非中枢神经系统和软脑膜反应相似。
核心结论
- EGFR T790M阳性NSCLC伴影像学检测的软脑膜转移患者可从奥希替尼80 mg每日一次治疗中获得临床获益。
研究设计与样本
- 回顾性分析AURA项目(AURA扩展、AURA2、AURA17、AURA3)中22例EGFR T790M阳性晚期NSCLC软脑膜转移患者,均接受奥希替尼80 mg每日一次治疗。
主要发现
- 软脑膜转移客观缓解率为55%(95%CI 32-76)。
- 中位软脑膜缓解持续时间未达到(95%CI 2.8-不可计算)。
- 中位软脑膜无进展生存期为11.1个月(95%CI 4.6-不可计算)。
- 中位总生存期为18.8个月(95%CI 6.3-不可计算)。
- 纵向分析显示AURA LM与BLOOM研究中患者的非中枢神经系统与软脑膜反应相似。
关键数值与推荐
- 患者入选条件为EGFR T790M阳性晚期NSCLC、既往EGFR-TKI治疗后进展,中枢神经系统转移(包括软脑膜转移)需神经无症状且稳定。
- 软脑膜转移影像学反应由神经影像学盲法独立中心审查,采用改良神经肿瘤学软脑膜转移反应评估标准。
临床怎么用
- 对于EGFR T790M阳性晚期NSCLC伴影像学检测的软脑膜转移患者,奥希替尼80 mg每日一次可作为治疗选择。
局限性
- 本分析为回顾性研究,样本量较小(22例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Osimertinib has shown promising activity in patients with leptomeningeal metastases (LMs) of EGFR-positive NSCLC at 160 mg once daily (qd) (BLOOM; NCT02228369). We report LM activity with osimertinib (80 mg qd) in a retrospective analysis of studies across the AURA program (AURA extension, AURA2, AURA17, and AURA3). METHODS: Patients with EGFR T790M-positive advanced NSCLC and progression after previous EGFR-tyrosine kinase inhibitor therapy received osimertinib (80 mg qd). Patients with central nervous system (CNS) metastases (including LMs) were eligible if the lesions were neurologically asymptomatic and stable. Patients with evidence of LMs at the study entry were retrospectively included for the analysis; brain scans were assessed for radiologic LM response by neuroradiologically blinded, independent central review per the modified Response Assessment in Neuro-Oncology LM criteria. LM objective response rate, duration of response, progression-free survival, and overall survival were assessed. A longitudinal analysis was performed to investigate the relationship between changes from the baseline in non-CNS tumor sizes and LM responses at each visit of patients in AURA LM and BLOOM studies. RESULTS: For the 22 patients included in the analysis, LM objective response rate was 55% (95% confidence interval [CI]: 32-76). Median LM duration of response was not reached (95% CI: 2.8-not calculable [NC]). Median LM progression-free survival and overall survival were 11.1 months (95% CI: 4.6-NC) and 18.8 months (95% CI: 6.3-NC), respectively. The longitudinal analysis revealed similar non-CNS and LM responses between the patients in AURA LM and BLOOM programs. CONCLUSIONS: Patients with EGFR T790M-positive NSCLC and radiologically detected LM obtained clinical benefit from osimertinib (80 mg qd).
引用
- Ahn MJ, Chiu CH, Cheng Y, et al. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. J Thorac Oncol. 2019. PMID: 31887431. doi:10.1016/j.jtho.2019.12.113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。